Below is a timeline of events surrounding Actos:
2007 Study suggests Avandia increases the risk of heart attack, cardiovascular disease, stroke, and death by 30 to 40 percent. The increased risk was not observed with Actos, a competing diabetes drug.
2008 Actos becomes the 10th most-prescribed drug in the United States. Sales of Actos reach $4.6 billion worldwide.
August 23, 2010 Study published in the journal Circulation: Cardiovascular Quality and Outcomes, shows that the risk of heart attack and acute heart failure from Actos is as great as Avandia.
June 9, 2011 French Agency for the Safety of Health Products withdraws Actos from the market due to a study linking Actos and increased risk of bladder tumors.
June 10, 2011 Germany's Federal Institute for Drugs and Medical Devices advises doctors against prescribing Actos, based on the correlation between the drug and higher incidence of bladder cancer.
June 15, 2011 The US Food and Drug Administration announces a link between Actos and increased incidence of bladder cancer, updating the warning label.